PL2769992T3 - Przeciwciała ludzkie o wysokim powinowactwie względem ludzkiego receptora IL-4 - Google Patents

Przeciwciała ludzkie o wysokim powinowactwie względem ludzkiego receptora IL-4

Info

Publication number
PL2769992T3
PL2769992T3 PL14162081T PL14162081T PL2769992T3 PL 2769992 T3 PL2769992 T3 PL 2769992T3 PL 14162081 T PL14162081 T PL 14162081T PL 14162081 T PL14162081 T PL 14162081T PL 2769992 T3 PL2769992 T3 PL 2769992T3
Authority
PL
Poland
Prior art keywords
human
receptor
high affinity
antibodies
human antibodies
Prior art date
Application number
PL14162081T
Other languages
English (en)
Polish (pl)
Inventor
Sean Stevens
Tammy T. Huang
Joel H. Martin
Jeanette L. Fairhurst
Ashique Rafique
Marcela Torres
Kevin J. Pobursky
Raymond W. Leidich
Joan A. Windsor
Warren R. Mikulka
Diana M. Ahrens
Ergang Shi
Nicholas J. Papadopoulos
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of PL2769992T3 publication Critical patent/PL2769992T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
PL14162081T 2006-10-02 2007-10-02 Przeciwciała ludzkie o wysokim powinowactwie względem ludzkiego receptora IL-4 PL2769992T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US84869406P 2006-10-02 2006-10-02
US95773807P 2007-08-24 2007-08-24
PCT/US2007/021210 WO2008054606A2 (en) 2006-10-02 2007-10-02 High affinity human antibodies to human il-4 receptor
EP14162081.5A EP2769992B1 (en) 2006-10-02 2007-10-02 High affinity human antibodies to human IL-4 receptor
EP07867197.1A EP2069403B1 (en) 2006-10-02 2007-10-02 High affinity human antibodies to human il-4 receptor

Publications (1)

Publication Number Publication Date
PL2769992T3 true PL2769992T3 (pl) 2021-08-02

Family

ID=39344836

Family Applications (2)

Application Number Title Priority Date Filing Date
PL14162081T PL2769992T3 (pl) 2006-10-02 2007-10-02 Przeciwciała ludzkie o wysokim powinowactwie względem ludzkiego receptora IL-4
PL07867197T PL2069403T3 (pl) 2006-10-02 2007-10-02 Przeciwciała ludzkie o wysokim powinowactwie wobec receptora ludzkiej IL-4

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL07867197T PL2069403T3 (pl) 2006-10-02 2007-10-02 Przeciwciała ludzkie o wysokim powinowactwie wobec receptora ludzkiej IL-4

Country Status (34)

Country Link
US (4) US7605237B2 (OSRAM)
EP (3) EP2069403B1 (OSRAM)
JP (1) JP2010505418A (OSRAM)
KR (1) KR101474227B1 (OSRAM)
CN (1) CN101522716B (OSRAM)
AU (1) AU2007314522C9 (OSRAM)
BR (1) BRPI0719953B8 (OSRAM)
CA (1) CA2664343C (OSRAM)
CO (1) CO6160305A2 (OSRAM)
CR (1) CR10689A (OSRAM)
CY (1) CY1115551T1 (OSRAM)
DK (2) DK2769992T3 (OSRAM)
DO (1) DOP2009000058A (OSRAM)
ES (2) ES2859825T3 (OSRAM)
HR (2) HRP20140512T1 (OSRAM)
HU (1) HUE054090T2 (OSRAM)
IL (1) IL197479A (OSRAM)
LT (1) LT2769992T (OSRAM)
MA (1) MA31138B1 (OSRAM)
ME (1) ME00616B (OSRAM)
MX (1) MX2009003393A (OSRAM)
MY (1) MY149079A (OSRAM)
NI (1) NI200900041A (OSRAM)
NO (1) NO347180B1 (OSRAM)
NZ (1) NZ576040A (OSRAM)
PL (2) PL2769992T3 (OSRAM)
PT (2) PT2069403E (OSRAM)
RS (2) RS53340B (OSRAM)
RU (1) RU2445318C2 (OSRAM)
SI (2) SI2069403T1 (OSRAM)
TN (1) TN2009000110A1 (OSRAM)
UA (1) UA98943C2 (OSRAM)
WO (1) WO2008054606A2 (OSRAM)
ZA (1) ZA200901617B (OSRAM)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
SI1523496T1 (sl) 2002-07-18 2011-11-30 Merus B V Rekombinantno proizvajanje zmesi protiteles
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP2395017A3 (en) 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
EP2604628A3 (en) 2007-12-21 2013-08-21 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4R) - 173
EP2556747B1 (en) 2008-06-27 2020-12-02 Merus N.V. Antibody producing transgenic mice
KR20110049802A (ko) 2008-07-25 2011-05-12 인스티튜트 포 리서치 인 바이오메드슨 중화 항-인플루엔자 ａ 바이러스 항체 및 이의 용도
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
AU2014216019B2 (en) * 2008-10-29 2016-04-21 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to Human IL-4 receptor
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
PT2564695E (pt) 2009-07-08 2015-06-03 Kymab Ltd Modelos animais e moléculas terapêuticas
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
DK2505654T4 (da) 2010-02-08 2020-07-27 Regeneron Pharma Mus med fælles letkæde
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
RU2601297C2 (ru) 2010-06-22 2016-10-27 Ридженерон Фармасьютикалз, Инк. Мыши, экспрессирующие гибридную легкую цепь иммуноглобулина
CA3250882A1 (en) * 2010-08-02 2025-11-29 Regeneron Pharamaceuticals, Inc. Mice that Make Binding Proteins Comprising VL Domains
CN106267189B (zh) 2010-10-06 2021-02-26 瑞泽恩制药公司 含有抗白介素-4受体(il-4r)的抗体的稳定制剂
ES2704038T3 (es) 2011-05-24 2019-03-13 Zyngenia Inc Complejos multiespecíficos multivalentes y monovalentes y sus usos
CN102830228B (zh) * 2011-06-15 2015-01-21 格诺思博生物科技(上海)有限公司 定量分析循环肿瘤细胞的试剂及试剂盒
AR087329A1 (es) * 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
EA036047B1 (ru) 2011-07-11 2020-09-18 Икнос Сайенсиз Са Антитела, которые связываются с ox40, и их применение
LT2734545T (lt) 2011-07-18 2019-05-10 Institute For Research In Biomedicine Antikūnai, neutralizuojantys influenza a virusą, ir jų panaudojimo būdai
MY172718A (en) 2011-08-05 2019-12-11 Regeneron Pharma Humanized universal light chain mice
MX363642B (es) 2011-09-16 2019-03-28 Regeneron Pharma Metodos para reducir los niveles de lipoproteina (a) administrando un inhibidor de proproteina convertasa subtilisina kexina-9 (pcsk9).
WO2013041844A2 (en) 2011-09-19 2013-03-28 Kymab Limited Antibodies, variable domains & chains tailored for human use
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
KR102081657B1 (ko) 2011-12-20 2020-02-26 리제너론 파마슈티칼스 인코포레이티드 인간화 경쇄 마우스
CN104302170B (zh) 2012-03-16 2016-09-28 瑞泽恩制药公司 生产具有ph依赖性结合特性的抗原结合蛋白的小鼠
NZ730271A (en) 2012-03-16 2022-09-30 Regeneron Pharma Non-human animals expressing ph-sensitive immunoglobulin sequences
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
ES2665793T3 (es) 2012-03-16 2018-04-27 Regeneron Pharmaceuticals, Inc. Anticuerpos de cadena ligera modificada mediante ingeniería genética con histidina y roedores modificados genéticamente para la generación de los mismos
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
CA2870821C (en) 2012-04-20 2022-06-14 Merus B.V. Methods and means for the production of ig-like molecules
KR102307248B1 (ko) 2012-08-21 2021-10-01 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
NZ630178A (en) 2012-09-07 2017-06-30 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r antagonist
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
DK2958941T3 (da) 2013-02-20 2019-06-24 Innate Pharma Forbindelse, der binder specifikt til kir3dl2, til anvendelse til behandling af perifert t-cellelymfom
ES2678221T3 (es) * 2013-02-20 2018-08-09 Regeneron Pharmaceuticals, Inc. Animales no humanos con secuencias de cadena pesada de inmunoglobulina modificadas
US10150800B2 (en) 2013-03-15 2018-12-11 Zyngenia, Inc. EGFR-binding modular recognition domains
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
MX368068B (es) * 2013-06-21 2019-09-18 Sanofi Biotechnology Antagonista de il-4r para usarse para tratar la poliposis nasal.
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
NL2013554B1 (en) 2013-10-01 2016-01-08 Kymab Ltd Animal models and therapeutic molecules.
LT3052192T (lt) 2013-10-02 2020-12-10 Medimmune, Llc Neutralizuojantys antikūnai prieš gripą a ir jų naudojimas
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
WO2015123777A1 (en) * 2014-02-19 2015-08-27 Cangene Corporation Methods of modulating an immune response
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
KR20160120735A (ko) 2014-02-28 2016-10-18 리제너론 파아마슈티컬스, 인크. Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법
BR112016021679A2 (pt) 2014-03-21 2018-12-04 Regeneron Pharmaceuticals, Inc. proteína de ligação ao antígeno, métodos de produção de uma proteína de ligação ao antígeno e de identificação de uma ou mais proteínas de ligação ao antígeno, hibridoma, ácido nucleico, célula, e, animal não humano geneticamente modificado.
BR112016021572A2 (pt) 2014-03-21 2017-10-03 Regeneron Pharma Métodos para preparar um animal não humano geneticamente modificado e para produzir proteínas de ligação, hibridoma, ácido nucleico, célula, e, proteína de ligação
AU2015289805B2 (en) 2014-07-15 2020-06-25 Humabs Biomed Sa Neutralizing anti-influenza B antibodies and uses thereof
WO2016023916A1 (en) 2014-08-12 2016-02-18 Kymab Limited Treatment of disease using ligand binding to targets of interest
WO2016071701A1 (en) 2014-11-07 2016-05-12 Kymab Limited Treatment of disease using ligand binding to targets of interest
CA2967602C (en) 2014-11-14 2024-09-24 Regeneron Pharmaceuticals, Inc. METHODS OF TREATMENT OF CHRONIC SINUSITIS WITH NASAL POLYPOSIS BY ADMINISTRATION OF AN IL-4R ANTAGONIST
WO2016144876A2 (en) * 2015-03-06 2016-09-15 Sorrento Therapeutics, Inc. Antibody therapeutics that bind jag1
CA2979702A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
PL3277725T3 (pl) 2015-03-30 2021-06-14 Regeneron Pharmaceuticals, Inc. Regiony stałe łańcucha ciężkiego o zmniejszonym wiązaniu do receptorów Fc gamma
CN113861294B (zh) 2015-04-02 2024-03-08 英特维特国际股份有限公司 针对犬白介素-4受体α的抗体
PL3303384T3 (pl) 2015-06-01 2022-01-03 Medimmune, Llc Neutralizujące cząsteczki wiążące przeciw grypie i ich zastosowania
CN106699888B (zh) * 2015-07-28 2020-11-06 上海昀怡健康科技发展有限公司 一种pd-1抗体及其制备方法和应用
TWI870789B (zh) * 2015-08-04 2025-01-21 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
CN106939047B (zh) 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
CA3010313A1 (en) 2016-01-13 2017-07-20 Medimmune, Llc Method of treating influenza a
CA3014202A1 (en) 2016-02-19 2017-08-24 Regeneron Pharmaceuticals, Inc. Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist
CN107474134B (zh) * 2016-06-08 2021-07-27 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
US11771743B2 (en) 2016-09-01 2023-10-03 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an IL-4R antagonist
US10485844B2 (en) 2016-09-22 2019-11-26 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
JP7164530B2 (ja) 2016-09-22 2022-11-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ－４ｒ阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法
EP3525820A4 (en) * 2016-10-17 2020-09-16 Vanderbilt University ANTIBODIES AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS AND THEIR USE METHODS
TWI857389B (zh) 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
WO2018112334A1 (en) 2016-12-16 2018-06-21 Bluefin Biomedicine, Inc. Anti-cub domain-containing protein 1 (cdcp1) antibodies, antibody drug conjugates, and methods of use thereof
KR102751957B1 (ko) 2017-04-13 2025-01-09 리제너론 파마슈티칼스 인코포레이티드 Il33 및 il1rl1을 코딩하는 유전자에서의 위험 대립유전자를 갖는 환자에서의 폐 질환의 치료 및 저해
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
CN107216388B (zh) * 2017-08-07 2020-05-05 广州泰诺迪生物科技有限公司 一种治疗丙型肝炎病毒药物的制备方法和用途
EP4344706A3 (en) 2017-10-30 2024-05-22 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
CN108373505B (zh) 2018-04-20 2019-08-20 北京智仁美博生物科技有限公司 抗il-4r抗体及其用途
CN120227453A (zh) 2018-05-13 2025-07-01 瑞泽恩制药公司 用于通过施用il-4r抑制剂治疗特应性皮炎的方法
CN110540590B (zh) 2018-05-29 2023-08-18 康诺亚生物医药科技（成都）有限公司 一种自免疫抑制物的开发和应用
WO2020018511A1 (en) * 2018-07-16 2020-01-23 Regeneron Pharmaceuticals, Inc. Non-human animal models of ditra disease and uses thereof
KR102840973B1 (ko) * 2018-08-24 2025-07-30 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 인간 il-4r 결합 항체, 이의 항원 결합 단편, 및 이의 의학적 용도
EP3878868B1 (en) * 2018-11-09 2024-10-09 Ajou University Industry-Academic Cooperation Foundation Human antibody having high affinity to human il-4 receptor alpha, and use thereof
CN111514292B (zh) * 2018-12-25 2023-06-20 江苏荃信生物医药股份有限公司 抗人白介素4受体α单克隆抗体的制药用途
MX2021010560A (es) 2019-03-06 2021-11-12 Regeneron Pharma Inhibidores de la via il-4/il-13 para una eficacia aumentada en el tratamiento de cancer.
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
US20220184127A1 (en) * 2019-04-08 2022-06-16 Phanes Therapeutics, Inc. Humanized anti-dll3 chimeric antigen receptors and uses thereof
CN112010977B (zh) 2019-05-29 2022-04-26 山东博安生物技术股份有限公司 抗白介素4受体(il-4r)的抗体及其应用
BR112022000740A2 (pt) 2019-07-16 2022-07-05 Sanofi Biotechnology Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r
CN112279914A (zh) * 2019-07-25 2021-01-29 苏州丁孚靶点生物技术有限公司 Il4ra抗体、基因、载体、宿主细胞和il4ra拮抗剂
EP4010373A1 (en) 2019-08-05 2022-06-15 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
KR20220042217A (ko) 2019-08-05 2022-04-04 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 치료하고 알레르겐-특이적 면역치료요법을 증진시키기 위한 방법
EP3992974A1 (en) 2020-11-02 2022-05-04 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
KR20220110829A (ko) 2019-12-09 2022-08-09 사노피 바이오테크놀로지 디지털 식별된 il-4/il-13 관련 장애의 치료 방법
US20230075244A1 (en) * 2020-02-20 2023-03-09 The Feinstein Institutes For Medical Research Agonist antibodies against endoglin and uses thereof
MX2022010217A (es) 2020-02-21 2022-09-19 Jiangsu Hengrui Pharmaceuticals Co Ltd Composicion farmaceutica que contiene anticuerpo anti-il-4r y uso de la misma.
CN119859187A (zh) * 2020-02-27 2025-04-22 正大天晴药业集团股份有限公司 结合il4r的抗体及其用途
JP2023520676A (ja) 2020-03-27 2023-05-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ－４ｒアンタゴニストを投与することによりアトピー性皮膚炎を処置するための方法
WO2021207709A1 (en) * 2020-04-10 2021-10-14 Seattle Children's Hospital (dba Seattle Children's Research Institute) Binders and chimeric antigen receptors specific for interleukin-1 receptor accessory protein
CN113527485B (zh) 2020-04-17 2024-11-15 湖南麦济生物技术股份有限公司 抗人白细胞介素-4受体α抗体及其制备方法和应用
CN113549151A (zh) * 2020-04-24 2021-10-26 苏州康乃德生物医药有限公司 与人IL-4Rα中特定表位结合的抗体及其应用
CN115768516A (zh) 2020-05-22 2023-03-07 瑞泽恩制药公司 通过施用il-4r抑制剂治疗嗜酸细胞性食管炎的方法
US20230279124A1 (en) 2020-07-17 2023-09-07 Gi Innovation, Inc. Fusion protein comprising ige fc receptor alpha subunit extracellular domain and anti-il-4r antibody, and use thereof
KR102697769B1 (ko) 2020-09-14 2024-08-23 아주대학교산학협력단 인터루킨-4 수용체 알파 서브유닛과 인터루킨-5 수용체 알파 서브유닛에 동시에 결합하는 이중특이항체 및 이의 용도
CA3194111A1 (en) 2020-10-05 2022-04-14 Christine XU Methods for treating asthma in pediatric subjects by administering an il-4r antagonist
CN116583539A (zh) 2020-12-22 2023-08-11 江苏恒瑞医药股份有限公司 抗il-4r抗体或其抗原结合片段的复合物及医药用途
KR20230130681A (ko) 2021-01-08 2023-09-12 리제너론 파아마슈티컬스, 인크. Il-4r 길항제 투여에 의한 땅콩 알레르기를 치료하는방법 및 땅콩 알레르기원 특이적 면역치료를 강화하는 방법
JP2024505390A (ja) * 2021-01-08 2024-02-06 ブリストル－マイヤーズ スクイブ カンパニー 第ｘｉａ因子阻害剤としての抗体および抗原結合ペプチド、およびその使用
EP4377345A1 (en) 2021-07-26 2024-06-05 Sanofi Biotechnology Methods for treating chronic spontaneous urticaria by administering an il-4r antagonist
TWI876192B (zh) * 2021-08-05 2025-03-11 美商美國禮來大藥廠 人類介白素-4受體α抗體
AU2022333073A1 (en) 2021-08-23 2024-04-04 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
CN119174816A (zh) * 2021-08-26 2024-12-24 正大天晴药业集团股份有限公司 抗il4r抗体的药物组合物及其用途
CA3235380A1 (en) 2021-10-20 2023-04-27 Elizabeth Laws Methods for treating prurigo nodularis by administering an il-4r antagonist
CA3241374A1 (en) 2021-12-30 2023-07-06 Gregory GEBA Methods for attenuating atopic march by administering an il-4/il-13 antagonist
CN118678972A (zh) 2022-01-29 2024-09-20 上海盛迪医药有限公司 糖皮质激素的药物偶联物
CN119095875A (zh) 2022-03-02 2024-12-06 瑞泽恩制药公司 高滴度抗体的制造工艺
IL316264A (en) 2022-05-02 2024-12-01 Regeneron Pharma Antibody formulations against interleukin-4 receptor (IL-4R)
EP4518839A2 (en) 2022-05-02 2025-03-12 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity
CN119546337A (zh) 2022-07-08 2025-02-28 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗小儿嗜酸性粒细胞性食管炎的方法
CN120091829A (zh) 2022-08-29 2025-06-03 赛诺菲生物技术公司 通过施用il-4r拮抗剂治疗慢性诱导性寒冷性荨麻疹的方法
TW202432598A (zh) 2022-11-01 2024-08-16 美商再生元醫藥公司 藉由投予il-4r拮抗劑治療手足皮膚炎的方法
JP2025541690A (ja) 2022-11-23 2025-12-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ－４ｒアンタゴニストを投与することによる、骨成長を改善するための方法
AU2024241290A1 (en) 2023-03-22 2025-11-06 Regeneron Pharmaceuticals, Inc. Methods for treating chronic obstructive pulmonary disease (copd) by administering an il-4r antagonist
TW202502820A (zh) 2023-03-27 2025-01-16 美商再生元醫藥公司 藉由投予ｉｌ—４ｒ拮抗劑治療嗜酸性球性胃腸炎之方法
TW202529831A (zh) 2023-10-02 2025-08-01 美商再生元醫藥公司 藥物遞輸裝置安全系統
US20250145662A1 (en) 2023-11-02 2025-05-08 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity using stress
WO2025137344A1 (en) 2023-12-20 2025-06-26 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods
WO2025221640A1 (en) 2024-04-15 2025-10-23 Sanofi Biotechnology Methods for treating chronic rhinosinusitis without nasal polyps by administering an il-4r antagonist

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7186A (en) 1850-03-19 fetchec
US809A (en) 1838-06-27 Improved mode of changing the poles of electro-magnets
GB8808015D0 (en) * 1988-04-06 1988-05-05 Ritter M A Chemical compounds
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
SG48760A1 (en) 1992-07-24 2003-03-18 Abgenix Inc Generation of xenogenetic antibodies
US5714146A (en) 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
EP0604693A1 (en) * 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
ZA946875B (en) * 1993-09-07 1995-07-06 Smithkline Beecham Corp Recombinant il4 antibodies useful in treatment of il4 mediated disorders
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
PT2990420T (pt) * 2000-05-26 2017-03-16 Immunex Corp Uso de anticorpos de recetor de interleucina-4 e composições dos mesmos
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2468733C (en) * 2001-11-30 2013-06-11 Biogen Idec Ma Inc. Antibodies against monocyte chemotactic proteins
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
NZ547588A (en) * 2003-11-07 2009-05-31 Immunex Corp Antibodies that bind interleukin-4 receptor
CA2550933A1 (en) * 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
AU2005219837A1 (en) * 2004-02-27 2005-09-15 Regeneron Pharmaceuticals, Inc. IL-4/IL-13 sepecific polypetides and therapeutic uses thereof
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
TWI307630B (en) * 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
TWI306862B (en) * 2005-01-03 2009-03-01 Hoffmann La Roche Antibodies against il-13 receptor alpha 1 and uses thereof
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor

Also Published As

Publication number Publication date
AU2007314522B8 (en) 2013-04-11
MY149079A (en) 2013-07-15
US7794717B2 (en) 2010-09-14
US20100021476A1 (en) 2010-01-28
PT2769992T (pt) 2021-03-11
MEP11109A (en) 2011-12-20
BRPI0719953A2 (pt) 2014-04-29
CO6160305A2 (es) 2010-05-20
EP2069403A2 (en) 2009-06-17
US20100291107A1 (en) 2010-11-18
US20120135010A1 (en) 2012-05-31
DK2069403T3 (da) 2014-07-28
WO2008054606A3 (en) 2009-02-05
EP2769992A3 (en) 2015-01-21
BRPI0719953B8 (pt) 2021-05-25
CA2664343A1 (en) 2008-05-08
US7605237B2 (en) 2009-10-20
IL197479A0 (en) 2011-08-01
KR101474227B1 (ko) 2014-12-18
US8092802B2 (en) 2012-01-10
AU2007314522A1 (en) 2008-05-08
SI2069403T1 (sl) 2014-09-30
CN101522716A (zh) 2009-09-02
BRPI0719953B1 (pt) 2019-04-24
KR20090088865A (ko) 2009-08-20
ME00616B (me) 2011-12-20
NO20091758L (no) 2009-05-04
US8338135B2 (en) 2012-12-25
CR10689A (es) 2009-06-24
DOP2009000058A (es) 2009-04-30
US20080160035A1 (en) 2008-07-03
EP2769992B1 (en) 2020-12-30
HUE054090T2 (hu) 2021-08-30
SI2769992T1 (sl) 2021-04-30
ES2466669T3 (es) 2014-06-10
ZA200901617B (en) 2009-12-30
HRP20210408T1 (hr) 2021-04-30
HK1131790A1 (en) 2010-02-05
DK2769992T3 (da) 2021-03-22
AU2007314522A8 (en) 2013-04-11
RU2009116608A (ru) 2010-11-10
NI200900041A (es) 2011-10-17
MX2009003393A (es) 2009-05-11
NZ576040A (en) 2011-06-30
RU2445318C2 (ru) 2012-03-20
CN101522716B (zh) 2013-03-20
UA98943C2 (ru) 2012-07-10
HRP20140512T1 (hr) 2014-07-04
JP2010505418A (ja) 2010-02-25
TN2009000110A1 (en) 2010-08-19
PT2069403E (pt) 2014-07-18
LT2769992T (lt) 2021-04-12
AU2007314522B2 (en) 2013-02-21
MA31138B1 (fr) 2010-02-01
ES2859825T3 (es) 2021-10-04
CY1115551T1 (el) 2017-01-04
EP2069403B1 (en) 2014-05-07
IL197479A (en) 2014-03-31
AU2007314522C1 (en) 2013-06-27
EP2769992A2 (en) 2014-08-27
RS53340B (sr) 2014-10-31
EP3845563A3 (en) 2021-11-24
NO347180B1 (no) 2023-06-19
PL2069403T3 (pl) 2015-08-31
EP3845563A2 (en) 2021-07-07
AU2007314522A2 (en) 2009-07-02
RS61650B1 (sr) 2021-04-29
AU2007314522C9 (en) 2013-08-01
CA2664343C (en) 2016-04-26
WO2008054606A2 (en) 2008-05-08
HK1200846A1 (en) 2015-08-14

Similar Documents

Publication Publication Date Title
ZA200901617B (en) High affinity human antibodies to human IL-4 receptor
IL211726A0 (en) High affinity human antibodies to human il-4 receptor
HUS1700029I1 (hu) Nagy affinitású PCSK9 elleni humán testek
IL196701A0 (en) HUMAN ANTIBODIES TO ErbB2
ZA200900395B (en) Antibodies directed to +-Vß6 and uses thereof
SI2949666T1 (sl) Človeška anti alfa-sinukleinska protitelesa
IL197937A0 (en) Antibodies to lymphotoxin-alpha
IL193604A0 (en) Methods of using antibodies against human il-22
IL201034A0 (en) Novel human anti-r7v antibodies and uses thereof
IL199446A0 (en) Antibodies to cd200r
ZA200902346B (en) Antibodies to lymphotoxin-alpha
ZA200809771B (en) High affinity antibodies to human IL-6 receptor
HRP20190159T1 (hr) Antitijela humanog anti-alfa-sinukleina